Aoxing Pharmaceutical Company, Inc. Reports Earnings Results for the Year Ended June 30, 2016
October 04, 2016
Share
Aoxing Pharmaceutical Company, Inc. reported earnings results for the year ended June 30, 2016. For the period, the company’s sales were $32,329,525 against $25,481,199 a year ago. Income from operations was $6,228,051 against $8,695,657 a year ago. Income before income taxes was $2,885,825 against $3,114,104 a year ago. Net income was $2,243,580 against $5,818,473 a year ago. Net income attributable to shareholders of the company was $2,061,224 against $5,494,713 a year ago. Earnings per share basic diluted were $0.03 against $0.09 a year ago. The increase in revenue was primarily attributable to the increase in the sales of other herbaltherapeutics products, which supplemented the continuing strong sales of the company's Zhongtong'an.
Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company specializing in research, development, manufacturing and distribution of a range of narcotic, pain-management and addiction treatment pharmaceutical products. The Company holds approximately 140 drug production certificates covering narcotic pain-management, prescription medicines, over-the-counter (OTC) and active pharmaceutical ingredient (API) products. Its products include prescription drugs, such as Tilidine hydrochloride, Zhongtong'an and Humifuse Euphorbia Herb Tablet, and OTC drugs, such as Shanmei Capsule, Shaoshang Tincture, Yiqi Qiangshen Granule, Xiaopiling Granule, Xiongjushangqing Tablet, Juyuansuanbijia Oral Solutions, Longdanxiegan Tablet, Fenka Tablet, Shujinhuoxue Tablet, Fuketiaojing Tablet, Qingnao Jiangya Tablet, Yuanhu Pain Management Tablet, Bushenqiangshen Tablet, Baiziyangxin Pill, Qingguo Pill, Liuweidihuang Pill, Zhibaidihuang Pill, Xiaoyao Pill and Tianwangbuxin Pill.
AOXING PHARMACEUTICAL COMPANY, INC. 
